EpimAb of Shanghai Raises $120 Million for Bispecific Antibodies
March 23, 2021 at 06:20 AM EDT
EpimAb of Shanghai raised $120 million in a Series C financing for its portfolio of bispecific antibody therapies. Proceeds from the round will be used to fund clinical development of EMB-01, EMB-02 and EMB-06, and to expand the company’s pipeline of novel bispecific antibodies and other biologics, which are mainly focused on oncology indications. The financing was co-led by China Merchants Bank International and Mirae Asset Financial Group. More details.... Share this with colleagues: // //
